Abstract
Purpose.
To compare the in vitro drug resistance profiles of advanced stage primary and recurrent
epithelial ovarian cancer specimens using the tritiated thymidine uptake assay.
Methods.
Extreme drug resistance (EDR) to cisplatin, paclitaxel, 4-hydroxycyclophosphamide,
and topotecan was determined for an unselected population of primary and metastatic
malignant ovarian tissues, synchronous tumors (primary and metastatic tissues obtained
from the same patient at diagnosis), and metachronous lesions (specimens from the
same patient before and after chemotherapy).
Results.
For the large unselected population of malignant tissues (total, N = 6990; primary ovarian, N = 2031; metastatic ovarian, N = 4959), no statistically significant differences were discovered between primary
tissues and metastatic lesions when a comparison was made between the percentage of
tumors from each group that exhibited extreme drug resistance to the agents assayed.
From the library of 6990 specimens, 119 synchronous pairings were identified. These
synchronous lesions did not differ significantly in the %EDR between primary and metastatic
sites in the same patient; approximately 10% shifted between low drug resistance and
EDR. A total of 334 metachronous pairings were identified and the percentage of tissues
that exhibited EDR also failed to show a significant difference when primary tumors
were compared with matched recurrences in the same patient.
Conclusions.
For the agents studied, acquired resistance was not a function of disease site. In
vitro drug resistance observed at recurrence was not influenced significantly by intervening
therapy. It is possible that assay results at diagnosis could be used to guide subsequent
therapy at relapse, especially when recurrent tissue is not available for analysis.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Recent advancements in the treatment of epithelial ovarian cancer.J. Obstet. Gynaecol. Res. 2001; 27: 61-75
- Cancer statistics, 2005.CA Cancer J. Clin. 2005; 55: 10-30
- Cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.N. Eng. J. Med. 1996; 334: 1-6
- Treatment of refractory and recurrent ovarian cancer.Semin. Oncol. 1999; 26: S8-S14
- Second-line treatment of ovarian cancer.Oncologist. 2000; 5: 26-35
- Principles of cancer management: chemotherapy.in: DeVita V. Hellman S. Rosenberg S. Cancer: principles and practice of oncology. Lippincott Williams and Wilkins, 2001
- In vitro determinations of drug response: a discussion of clinical applications.Princ. Pract. Oncol., Upd. 1993; 7: 1-16
- Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer.J. Clin. Oncol. 1999; 17: 1625-1631
- Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug doses.J. Natl. Cancer Inst. 1990; 82: 582-588
- Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.Breast Cancer Res. Treat. 2001; 66: 225-237
- Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.Gynecol. Oncol. 2002; 87: 8-16
- Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: taxol resistance and MDR-1 expression.Contrib. Gynecol. Obstet. 1994; 19: 39-52
- Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model.Anticancer Res. 1993; 13: 1825-1829
- An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers.Biometrics. 1977; 33: 363-374
- Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.J. Natl. Cancer Inst. 1992; 84: 1793-1798
- Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.Am. J. Obstet. Gynecol. 1997; 176: 759-768
- A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate.Cancer Treat. Rep. 1979; 63: 1727-1733
- The clinical relevance of chemosensitivity testing in ovarian cancer.Cancer Detect. Prev. 1998; 22: 305-312
- In vitro chemosensitivity testing and mechanisms of drug resistance.Current Oncol. Rep. 1999; 1: 77-84
- Chemosensitivity testing in ovarian cancer.Cancer. 1993; 71: 1613-1620
- Biomarker conservation in primary and metastatic epithelial ovarian carcinoma.Gynecol. Oncol. 2000; 78: 130-136
- Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro.Breast Cancer Res. Treat. 1999; 53: 77-85
- Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.Anticancer Drugs. 1998; 9: 51-57
- Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer.Anticancer Res. 1998; 18: 1973-1978
- Medical decision making: a Bayesian approach to laboratory testing.Med. Sect. Proc. 1987; : 27-37
- Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.Cancer J. Sci. Am. 1999; 5: 174-178
- American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.J. Clin. Oncol. 2004; 22: 3631-3638
- Gynecologic Oncology Group trials in ovarian carcinoma.Semin. Oncol. 1997; 24: S2-10-S2-12
- Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbidity and impact on survival.Ann. Surg. Oncol. 1997; 4: 349-354
- Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study.Gynecol. Oncol. 1997; 66: 171-178
Article info
Publication history
Received:
January 30,
2005
Identification
Copyright
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
